AFM
ANTX icon

Anson Funds Management’s AN2 Therapeutics ANTX Stock Holding History

Anson Funds Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,500
Closed -$38K – 326
2022
Q1 		$38K Buy
+2,500
New +$37.9K ﹤0.01% 332

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Anson Funds Management's ANTX Position: Q2 2022 in Review

Anson Funds Management sold out of AN2 Therapeutics (ANTX) in Q2 2022, closing a stake of 2,500 shares — an estimated $38K sold.

Anson Funds Management first reported a position in ANTX in Q1 2022 and held it in 1 quarter. The position peaked at $38K in Q1 2022. 36 funds tracked by Wall St. Rank hold ANTX as of Q2 2022.

  • Anson Funds Management reported no remaining AN2 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Anson Funds Management sold 2,500 AN2 Therapeutics shares in Q2 2022, an estimated $38K.
  • Anson Funds Management first reported a position in AN2 Therapeutics in Q1 2022 and held it in 1 quarter.
  • Anson Funds Management's AN2 Therapeutics position peaked at $38K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2022.

Based on Anson Funds Management's 13F filing for Q2 2022, filed 15 Aug 2022.